Rep. David Taylor Sells Off Shares of Eli Lilly and Company (NYSE:LLY)

Representative David Taylor (Republican-Ohio) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on February 20th, the Representative disclosed that they had sold between $1,001 and $15,000 in Eli Lilly and Company stock on February 9th. The trade occurred in the Representative’s “DAVID TAYLOR TRUST > SCHWAB JOINT BROKERAGE #1 (HOME GROWN)” account.

Representative David Taylor also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Progressive (NYSE:PGR) on 2/10/2026.
• Sold $1,001 – $15,000 in shares of Parker-Hannifin (NYSE:PH) on 2/9/2026.
• Purchased $1,001 – $15,000 in shares of Visa (NYSE:V) on 2/9/2026.
• Purchased $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 2/9/2026.
• Purchased $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 2/9/2026.
• Purchased $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 2/9/2026.
• Purchased $1,001 – $15,000 in shares of Salesforce (NYSE:CRM) on 2/9/2026.
• Purchased $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 1/29/2026.
• Sold $1,001 – $15,000 in shares of Amgen (NASDAQ:AMGN) on 1/29/2026.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $1,057.38 on Tuesday. The business’s 50-day simple moving average is $1,054.73 and its 200-day simple moving average is $920.78. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95. The firm has a market cap of $997.49 billion, a price-to-earnings ratio of 46.07, a P/E/G ratio of 1.17 and a beta of 0.39.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, beating the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The company had revenue of $19.29 billion for the quarter, compared to the consensus estimate of $17.85 billion. During the same quarter last year, the company posted $5.32 earnings per share. The company’s revenue for the quarter was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a dividend of $1.73 per share. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is currently 30.15%.

Institutional Investors Weigh In On Eli Lilly and Company

A number of institutional investors have recently bought and sold shares of LLY. Sonoma Allocations LLC raised its stake in Eli Lilly and Company by 13.3% during the fourth quarter. Sonoma Allocations LLC now owns 1,443 shares of the company’s stock worth $1,516,000 after acquiring an additional 169 shares in the last quarter. Monetary Solutions Ltd acquired a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $140,000. Kera Capital Partners Inc. grew its holdings in shares of Eli Lilly and Company by 35.4% in the 4th quarter. Kera Capital Partners Inc. now owns 761 shares of the company’s stock worth $789,000 after purchasing an additional 199 shares during the last quarter. Walser Wealth Management Company A Ltd Liability Co acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth about $1,332,000. Finally, Copos Capital S.a r.l. bought a new position in Eli Lilly and Company during the 4th quarter valued at about $74,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Head‑to‑head trial: Novo Nordisk’s next‑gen obesity drug failed to demonstrate non‑inferiority to Lilly’s tirzepatide in an 84‑week study, boosting expectations that Lilly will maintain or grow market share in the lucrative weight‑loss category. Novo Nordisk’s obesity drug falls short against Eli Lilly’s (Reuters)
• Positive Sentiment: FDA label expansion & product launch: The FDA approved a four‑dose multi‑use KwikPen for Zepbound; Lilly announced immediate launch and said the self‑pay price option remains the same, which may lower friction for patients and improve adherence/retention. Eli Lilly’s Zepbound Gets FDA OK for Multi‑Dose Pen (WSJ)
• Positive Sentiment: Commercial positioning: Lilly’s KwikPen offers a month of doses in one device and a $299 self‑pay option, which investors view as a retention and convenience win that could support longer customer lifecycles and stable revenue per patient. Zepbound now available in multi‑dose KwikPen (PR Newswire)
• Positive Sentiment: Pipeline and combo data: Lilly reported positive data showing Taltz plus Zepbound outperformed Taltz alone in overweight/obese psoriasis patients — broadens use cases and supports incremental label/market opportunities. LLY expands pipeline with positive trial data (InsiderMonkey)
• Positive Sentiment: Institutional demand and analyst support: Reports show hedge funds and ETFs increased exposure to mega‑caps including Lilly, and some firms have recently raised price targets — supporting momentum and liquidity. Hedge funds’ Eli Lilly buying spree (Benzinga)
• Negative Sentiment: Insider/large‑holder selling flagged by data aggregators — large institutional rebalancing (e.g., Lilly Endowment sales reported) shows notable share dispositions in recent quarters; investors may watch whether selling continues or is one‑time reallocation. QuiverQuant note on insider & institutional activity

Analysts Set New Price Targets

Several research firms recently weighed in on LLY. HSBC reissued a “hold” rating and set a $1,070.00 price objective on shares of Eli Lilly and Company in a research report on Wednesday, December 10th. Zacks Research lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. Deutsche Bank Aktiengesellschaft increased their price objective on Eli Lilly and Company from $1,200.00 to $1,285.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Guggenheim lowered their price objective on shares of Eli Lilly and Company from $1,163.00 to $1,161.00 and set a “buy” rating on the stock in a research note on Tuesday, January 20th. Finally, Rothschild & Co Redburn upped their target price on shares of Eli Lilly and Company from $775.00 to $830.00 and gave the company a “neutral” rating in a research note on Monday, January 26th. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus price target of $1,228.54.

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio’s 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Taylor (Republican Party) ran for election to the U.S. House to represent Ohio’s 2nd Congressional District. He won in the general election on November 5, 2024.

David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor’s career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.